BiotechTube
Home/Breye Therapeutics/Ulrik Mouritzen
UM

Ulrik Mouritzen

CEO

Breye Therapeutics

Therapeutic Areas

OphthalmologyRetinal Diseases

Breye Therapeutics Pipeline

DrugIndicationPhase
DanegaptideDiabetic RetinopathyPhase 2
Oral P2X7 Receptor AntagonistsDiabetic Retinopathy / Age-related Macular DegenerationPreclinical

Leadership Team at Breye Therapeutics

PA
Peter Adamson
CSO
KG
Kaare G Rasmussen
Head of CMC
TB
Tom Biancardi
Financial Advisor
BE
Benedikte el-Bandak Lind
Head of Clinical Operations
MT
Magali Taiel
CMO Consultant
View full Breye Therapeutics profile